{
  "title": "Medicines and Allied Substances (Marketing Authorisation of Medicines) Regulations, 2019",
  "year": "2019",
  "date": "2019-11-22",
  "language": "en",
  "content": "22ndNovember,2019 Statutory Instruments 405\nGOVERNMENT OF ZAMBIA\nSTATUTORY INSTRUMENT NO.79 OF 2019\nThe Medicines and Allied Substances Act, 2013\n(ActNo.3of 2013)\nThe Medicines and Allied Substances (Marketing\nAuthorisation of Medicines) Regulations, 2019\nARRANGEMENTOFREGULATIONS\nPART I\nPRELIMINARYPROVISIONS\nRegulation\n1. Title\n2. Interpretation\nPART II\nMARKETINGAUTHORISATIONOFMEDICINES\n3. Applicationformarketingauthorisation\n4. Requestforadditionalinformation\n5. Grantof marketingauthorisation\n6. Rejectionofapplication\n7. Validityofmarketingauthorisation\n8. Annualretentionfee\n9. Amendmentofmarketingauthorisation\n10. Surrenderofmarketingauthorisation\n11. Transferof marketingauthorisation\n12. Suspensionofmarketingauthorisation\n13. Restorationofmarketingauthorisation\n14. Revocationofmarketingauthorisation\n15. Applicationforduplicatemarketingauthorisation\n16. Renewalofmarketingauthorisation\n17. Localresponsibleperson\n18. Registerofmarketingauthorisations\nCopiesofthisStatutory Instrumentcan be obtained from the GovernmentPrinter,\nP.O.Box30136,10101Lusaka.PriceK64.00each.\n406 Statutory Instruments 22ndNovember,2019\nPART III\nCATEGORYOFDISTRIBUTIONOFMEDICINE\n19. Categoryofdistributionofmedicine\n20. RecategorisationofMedicine\nPART IV\nLABELLINGANDPACKAGING\n21. Labellingandpackagingrequirementsformedicine\n22. Packageinsertformedicine\n23. RevocationofstatutoryinstrumentNo.47of1993\nSCHEDULE\n22ndNovember,2019 Statutory Instruments 407\nINEXERCISEofthepowerscontainedinsections39and69ofthe\nMedicines and Allied Substances Act, 2013, the following\nRegulationsaremade:\nPART I\nPRELIMINARYPROVISIONS\n1. TheseRegulationsmaybecitedastheMedicinesandAllied Title\nSubstances(MarketingAuthorisationofMedicines)Regulations,\n2019.\n2. In these Regulations, unless the context otherwise Interpretation\nrequires—\n“ active pharmaceutical ingredient ” means a substance\nintendedtoexertpharmacologicalactivityorotherdirect\neffect in the diagnosis, cure, mitigation, treatment or\npreventionofdiseaseortoaffectthestructureandfunction\nofthe body,andmaybeusedasis orinthemanufacture\nofapharmaceuticaldosageform;\n“ batch ” means a defined quantity of a starting material,\npackaging or medicinal product processed in a single\nprocess or series of processes and expected to be\nhomogeneous;\n“bio-availability”meanstherateandextentofavailabilityof\nan active pharmaceutical ingredient from a dosage form\nas determined by its concentration time curve in the\nsystemiccirculationorbyitsexcretioninurine;\n“bio-equivalencedata”meanstheabsenceofasignificant\ndifference in the rate and extent to which the active\ningredientoractivemoietyinpharmaceuticalalternatives\nbecomesavailableatthesiteofdrugactionadministered;\n“ commercial pack ” means the presentation of a finished\nmedicinalproductasitwillbeplacedonmarket;\n“composition”meansatabulationofingredientsrepresented\ninformofproportion,degreeofstrength,qualityandpurity\nin which the ingredients are contained in a medicinal\nproduct;\n“container”meansabottle,jar,box,packet,sachetorother\nreceptacle,not beinga capsule or other article, inwhich\ntheproductisor is to beadministeredor consumed,and\nwhere the receptacle is or is to be contained in another\nreceptacle,includestheformerreceptaclebutnotthelatter\nreceptacle;\n“descriptionoftheproduct”meansafullvisualdescription\nofthemedicinalproduct,includingcolour,size,shapeand\nother relevant features;\n408 Statutory Instruments 22ndNovember,2019\n“dosageform”meanstheforminwhichamedicinalproduct\nispresented,suchassolution, suspension,elixir,eyedrop,\nemulsion,ointment,suppository,tabletorcapsule;\n“excipient”meansasubstanceintendedtobeusedasisor\nin the manufacture of a medicinal product for a specific\nfunction,butdoesnotexertpharmacologicalactivity;\n“ expiry date ” means the date given by the manufacturer\nandplacedonthe containerofamedicinal productupto\nwhichtheproductisexpectedtoremainwithinthegiven\nspecifications if stored according to manufacturer’s\ninstructions;\n“finishedpharmaceuticalproduct”meansaproductthathas\nundergoneallthestagesofproduction,includingpackaging\ninitsfinalcontainerandlabelling;\n“ formulation ” means the composition of a dosage form,\nincluding the characteristics of its raw materials and the\noperationsrequiredtoprocessit;\n“ general sale medicine (GS) ” means a medicine which is\nintendedtobesuppliedorsoldwithoutaprescriptionwith\norwithoutthesupervisionofaregisteredpharmacistina\npharmacyorinanyotherlicensedpremises;\n“generalsalemedicinesveterinary(GSV)”meansveterinary\nmedicinewhichisintendedtobesuppliedbyanyretailer\napprovedbytheAuthority;\n“herbalmedicine”includesaherb,herbal material,herbal\npreparationandfinishedherbalproductthatcontainsasan\nactiveingredient,apartofaplantorotherplantmaterial\nor combination;\n“holderofmarketingauthorisation”meansapersontowhom\namedicinalproducthasbeenissuedamarketauthorisation\nandisresponsibleforallaspectsofthemedicinalproduct\nincluding quality, safety, efficacy and compliance with\nconditionsofmarketingauthorisation;\n“internationalnonproprietaryname”meansauniquename\nof a medicine that is globally recognised and is public\nproperty;\n“labelling”meansaffixingtoordisplayingonacontaineror\npackage,theproductinformation,ingredientsandcontent\noftheproduct;\n“ local responsible person ” means a person residing in\nZambiaandappointedinaccordancewithregulation17;\n“marketingauthorisationnumber”meansanidentification\nnumber issuedtoa medicinalproductgrantedmarketing\nauthorisation;\n22ndNovember,2019 Statutory Instruments 409\n“ pharmacy medicine (P) ” means a medicine which is\nintendedtobesuppliedorsoldwithoutaprescriptionbut\nunderthesupervisionofaregisteredpharmacist;\n“ pharmacy medicines veterinary (PV) ” means veterinary\nmedicinewhichisintendedtobesuppliedbyaregistered\nveterinary surgeon, pharmacist or veterinary para\nprofessionalwithorwithoutaprescription;\n“prescriptiononlymedicine(POM)”meansamedicinewhich\nisintendedtobesupplied,soldordispensedonlyundera\nprescriptionissuedbyanauthorisedprescriber;\n“ prescriptiononlymedicineveterinary(POM V)” means\nveterinarymedicineswhichisintendedtobesuppliedon\nprescriptionbyaveterinarysurgeon;\n“ proprietaryname” means the trade orbrandname that is\nuniquetoaparticularmedicineandbywhichitisgenerally\nidentified;\n“qualitystandard”meansthespecificationsusedtocontrol\nthenature,strength,purity, composition,quantityorother\ncharacteristicsofaningredientorfinishedpharmaceutical\nproducttoensurethatitisfitforitspurpose;\n“shelflife”meanstheperiodoftimeduringwhichanactive\npharmaceuticalingredientormedicinalproduct,ifstored\ncorrectly, is expected to comply with the approved\nspecificationasdeterminedbystabilitystudiesonanumber\nof batches of the active pharmaceutical ingredient or\nmedicinalproduct;\n“ stability ” means the ability of a medicine to retain its\nproperties within approved specifications throughout its\nshelflife;\n“WHOtypecertificateofapharmaceuticalproduct”means\na certificate of the type defined in the World Health\nOrganisation certification scheme on the quality of\npharmaceuticalproductsininternationalcommerce;and\n“ veterinary medicine ” means a substance or mixture of\nsubstancesmanufactured,soldorpresentedforusein-\n(a)thediagnosis,treatment,mitigationorpreventionof\na disease,disorder,abnormal physical or mental\nstate,orthesymptomsthereof,inananimal;\n(b) restoring, correctingor beneficial modification of\norganicormentalfunctionsinananimal;and\n(c) an article intended for use as a component of any\narticlespecifiedinparagraphs(a)or(b),butdoes\nnotincludeamedicaldeviceoritscomponent,part\nor accessory\n410 Statutory Instruments 22ndNovember,2019\nApplication 3. (1) Apersonwhointendstoplaceamedicine onthemarket\nfor shallapplytotheAuthorityforamarketingauthorisationinFormI\nmarketing\nauthorisation setoutintheScheduleonpaymentofthefeesetoutintheMedicines\nS.I.No.38of andAlliedSubstances(Fees)Regulations,2016.\n2016\n(2) Theapplicationreferredtoinsub-regulation(1) shall be\naccompaniedby\n(a)atleasttwosamplesoftheproductinthesmallestproposed\ncommercialpacksize;\n(b)adossierwhichshallcontain—\n(i)a summaryand overviewof quality,non clinical\nandclinicaldata;\n(ii) chemical, pharmaceutical and biological data\nrelevanttotheapplication;\n(iii)nonclinicaldata,whereapplicable;and\n(iv)clinicalorbio-equivalencedata;\n(c)inthecaseofaherbalmedicine,documentationrelating\nto the quality assessment, safety assessment and\nefficacyassessmentofthe herbalmedicine;and\n(d) anyother information relatingto the safety, qualityand\nefficacy of the medicine in respect of which the\napplicationismade.\n(3) The Authority shall, on receipt of an application for a\nmarketing authorisation, conduct an assessment to evaluate the\nsafety,qualityandefficacyof themedicineinrespectofwhichthe\napplicationismade.\nRequestfor 4. TheAuthoritymayrequestanapplicanttosubmitadditional\nadditional informationorsamplesinrelationtoanapplicationinFormIIset\ninformation\noutintheScheduleonpaymentofaprescribedfee.\nGrant of 5. TheAuthorityshallgrantamarketingauthorisationinForm\nmarketing IIIsetoutintheSchedule,iftheAuthority issatisfied—\nauthorisation\n(a)withthe informationsubmittedonthesafety,qualityand\nefficacyofthemedicine;\n(b)withthelabelingandpackagingofthemedicine;\n(c) with the indications, dosage form, dosage and route of\nadministrationofthemedicine;and\n(d)thatthemedicineismanufacturedincompliancewiththe\nrequirements ofcurrent goodmanufacturingpractices\nasrecommendedbytheWorldHealthOrganisationor\nanyotherrecognisedentity.\n22ndNovember,2019 Statutory Instruments 411\n6. (1) TheAuthorityshall reject an applicationfor marketing Rejectionof\nauthorisationif— application\n(a)theapplicantfailstomeettherequirementsfortheissue\nofthemarketingauthorisation;\n(b)thereisinsufficientdatatosupportthesafety,qualityand\nefficacyoftheproduct;\n(c) in the case of a local manufacturer, the pharmaceutical\nlicencetomanufactureissuspendedorrevoked;\n(d)aningredientcontainedinthemedicineisbannedornot\nrecommended for any other reason as determined by\ntheAuthority;\n(e)themedicineinrespectofwhichtheapplicationismade\nisconsideredunregistrablebasedontreatmentguidelines\nordiseasepatternsintheRepublic;and\n(f) theapplicantprovides falseinformationintheapplication.\n(2) The Authority shall, where it refuses a marketing\nauthorisationundersubregulation(1),informtheapplicantinForm\nIVsetoutintheSchedule.\n7. Amarketingauthorisationisvalidforfiveyears,subjectto Validityof\nthetermsandconditionsofthemarketauthorisation. marketing\nauthorisation\n8. (1) The holder of a marketing authorisation shall pay an Annual\nannual retention fee to theAuthority in respect of the following retentionfee\nyear at the end of every year during which the authorisation is\nvalid,excepttheyearwhentheauthorisationisgranted.\n(2) Theannualretentionfeeforthefollowingyearshallbe—\n(a)effectivefrom1stJanuaryoftheyearfollowingthegrant\nofthemarketingauthorisation;and\n(b)paidtotheAuthorityby31st Decemberofeachyear.\n(3) Whereamarketingauthorisationisgrantedduringthelast\nquarterofacalendaryear,theholderofthemarketingauthorisation\nshall be exempted from paying the annual retention fee for the\nfollowingyear.\n(4) Wheretheholderofamarketingauthorisationfailstopay\ntheannualretentionfeeby31st Decemberforaparticularproduct\n(a)themarketingauthorisationissuedinrespectofthatproduct\nshallbesuspended;\n(b) theAuthority shall not authorise the importation of the\nproduct;\n412 Statutory Instruments 22ndNovember,2019\n(c) in case of locally manufactured products, theAuthority\nshall not authorise the continued manufacture of the\nproduct;and\n(d) themarketingauthorisationinrespectoftheproductmay\nberevokedbytheAuthority.\nAmendment 9. (1) Apersonwhowishestoamendamarketingauthorisation\nof marketing shallapplytotheAuthorityinFormVsetoutintheScheduleon\nauthorisation\npayment of a prescribed fee.\n(2) TheAuthorityshall,withinninetydaysfromthedate of\nreceipt of an application for the amendment of a marketing\nauthorisation,considertheapplicationandnotifytheholderofthe\nmarketingauthorisationofitsdecision.\nSurrenderof 10. Wheretheholderofamarketingauthorisationdecidesnot\nmarketing tocontinuewiththebusinesstowhichthe marketingauthorisation\nauthorisation\nrelates, the holder shall notify the Authority and surrender the\nmarketingauthorisation.\nTransfer of 11. (1) Amarketingauthorisationissolelyforusebytheholder\nmarketing ofthemarketingauthorisationandisnottransferabletoanyother\nauthorisation\npersonwithoutthepriorapprovaloftheAuthority.\n(2) Apersonwhowishestotransferamarketingauthorisation\nshallapplytotheAuthorityinFormVIsetoutintheScheduleon\npayment of a prescribed fee.\n(3) TheAuthorityshall,withinsixtydaysfromthedateofreceipt\nofthe applicationforthetransferofthe marketingauthorisation,\nnotifytheapplicantofthe decisionoftheAuthorityinrespectof\ntheapplication.\n(4) WheretheAuthorityapprovesthetransferofamarketing\nauthorisation, it shall issue a new marketing authorisation to the\ntransferee.\nSuspension 12. (1) TheAuthoritymaysuspendamarketingauthorisation\nof marketing if—\nauthorisation\n(a)thereareconcernsregardingthesafety,qualityorefficacy\nofthemedicinetowhichitrelates;\n(b)theholderofthemarketingauthorisationfailstopaythe\nannualretentionfee;\n(c)theholderofthemarketingauthorisation failstocomply\nwithanytermorconditionofthemarketing authorisation;\nor\n(d) the medicine in respect of which the marketing\nauthorisationwasissuedposesariskorthreattopublic\nhealth.\n22ndNovember,2019 Statutory Instruments 413\n(2) The Authority shall, before suspending a marketing\nauthorisation,givenoticetotheholderofamarketingauthorisation\noftheintentiontosuspendthemarketingauthorisationinFormVII\nsetoutintheSchedule.\n(3) The Authority shall, if the holder of a marketing\nauthorisationfailstoremedythedefectswithintheperiodspecified\nbytheAuthorityinthenoticeissuedinsub-regulation(2),suspend\nthemarketingauthorisationandnotifytheholderofthemarketing\nauthorisationinFormVIIIsetoutintheSchedule.\n(4) Theholderofamarketingauthorisationshall,duringthe\nperiodofsuspensionofamarketingauthorisation,quarantinethe\naffectedmedicineasdirectedbytheAuthorityattheholderofthe\nmarketingauthorisation’scost.\n13. (1) The Authority may restore a suspended marketing Restoration\nof\nauthorisationiftheAuthorityissatisfiedthatcorrectivemeasures\nmarketing\nhavebeen takenbythe holderof the marketingauthorisationas authorisation\ndirectedbytheAuthority.\n(2) The Authority shall issue the notice of restoration of a\nsuspended marketing authorisation in Form IX set out in the\nSchedule.\n14. (1) TheAuthoritymayrevoke amarketingauthorisation Revocation\nofmarketing\niftheholder—\nauthorisation\n(a) contravenes the terms and conditions of the marketing\nauthorisation;\n(b) manufactures medicine that does not comply with the\nqualitystandardforthatmedicine;\n(c)failstocomplywithcurrentgoodmanufacturingpractices;\n(d) fails to comply with the terms and conditions for the\nsuspensionunderregulation12;or\n(e)obtainedtheauthorisationonthebasisoffraud,negligence\normisrepresentation.\n(2) The Authority shall, before revoking a marketing\nauthorisation,givenoticetotheholderofthemarketingauthorisation\noftheintentiontorevokethemarketingauthorisationinFormX\nsetoutintheSchedule.\n(3) The Authority shall, where the holder of a marketing\nauthorisationfailstoremedythebreachesspecifiedinthenotice\nwithintheperiodspecifiedbytheAuthority,revokethemarketing\nauthorisationandnotifytheholderinFormXIsetoutintheSchedule.\n414 Statutory Instruments 22ndNovember,2019\n(4) The holder of a marketing authorisation shall, on the\nrevocationofthemarketingauthorisation,recallandquarantineor\ndisposeofthemedicinetowhichtherevocationrelatesasdirected\nbytheAuthorityattheholderofthemarketingauthorisation’scost.\nApplication 15. (1) Aholderofamarketingauthorisationwhosemarketing\nforduplicate authorisationislost,defacedordamagedmayapplyforaduplicate\nmarketing\nmarketing authorisation in Form XII set out in the Schedule on\nauthorisation\npayment of a prescribed fee.\n(2) TheAuthorityshall,withinfourteendaysofreceiptofan\napplication under subregulation (1), issue a duplicate marketing\nauthorisationtotheapplicant.\nRenewalof 16. (1) Apersonwhowishestorenewamarketingauthorisation\nmarketing shall applytotheAuthorityatleast one hundredandeightydays\nauthorisation\nbeforetheexpirydateofthemarketingauthorisationinFormXIII\nsetoutintheScheduleonpaymentofaprescribedfee.\n(2) Anapplicationfortherenewalofamarketingauthorisation\nshallbeaccompaniedby—\n(a) a consolidated report of any amendments made to the\nmarketingauthorisation,includingadversedrugreaction\nreportsandsafetyupdates;and\n(b)theproductqualityreviewreport.\n(3) TheAuthorityshallrenewamarketingauthorisationifthe\nholderhascompliedwiththetermsandconditionsofthemarketing\nauthorisation.\n(4) TheAuthorityshall,wheretheAuthorityrefusestorenew\namarketingauthorisation,notifytheapplicantinFormIVsetoutin\ntheSchedule.\n(5) Aholderofa marketingauthorisationwhoseapplication\nfor renewal has been rejected may submit an application for a\nmarketingauthorisationinaccordancewithregulation3.\nLocal 17. (1) Subject to the Companies Act, 2017 and any other\nresponsible relevantwrittenlaw,aforeignbasedapplicantshallappointalocal\nperson\nresponsiblepersonto—\nActNo.10\nof2017\n(a) submit anapplication,documentandsampleofproducts\ntotheAuthorityonbehalfoftheapplicantorholderof\nthemarketingauthorisation;and\n(b) receive the decision of the Authority relating to the\napplicationonbehalfof the applicant or holder ofthe\nmarketingauthorisation.\n22ndNovember,2019 Statutory Instruments 415\n(2) Subject to sub regulation (1), where the application is\ngranted, the holder of the marketing authorisation shall ensure\nthatalocalresponsiblepersonimplementsthepharmacovigilance\nplanonbehalfoftheforeignholderofthemarketingauthorisation.\n18. (1) The Authority shall, where it grants a marketing Categoriesof\nauthorisation,specifytheappropriate categoryof distributionof distribution\nofmedicines\nthemedicinewhichrelatestothemarketingauthorisation.\n(2) Apersonmaysellorsupplymedicineforhumanuseunder\nthefollowingcategories:\n(a)prescriptiononlymedicine;\n(b)pharmacymedicine;and\n(c)generalsalemedicine.\n(3) Apersonmaysellorsupplyveterinarymedicineunderthe\nfollowingcategories:\n(a)prescriptiononlymedicine-veterinary;\n(b)pharmacymedicineveterinary;and\n(c)generalsalemedicineveterinary.\n19. TheAuthorityshalltakeintoconsiderationthesafetyprofile Re-\nofthemedicinewhendeterminingthecategoryofdistributionand categorisation\nofmedicine\nmaymovecertainmedicinesfromonecategorytoanother.\n20. (1) A holder of a marketing authorisation shall label the Labelling\nprimarypackageorcontainerofamedicinetoshow— and\npackaging\nrequirements\n(a)thename anddosage formof the medicine;\nformedicine\n(b)thenameandquantityofactivepharmaceuticalingredient\norincaseofaherbalmedicine,abotanical,englishor\nothername,andthequantityofeachingredient;\n(c)thequantityorvolumeofthemedicineperunitpack;\n(d)theindicationsanddirectionsforuse,includingthetarget\nspeciesincaseofveterinarymedicine;\n(e)thestorageinstructions;\n(f) theexpirydate;\n(g)the batchnumber;\n(h)themarketingauthorisationnumber;\n(i) the name and address of the holder of the marketing\nauthorisation;\n416 Statutory Instruments 22ndNovember,2019\n(j)suitablecoding;\n(k) thenameofthemanufacturer,ifdifferentfromtheholder\nofthemarketingauthorisation;\n(l)thecategoryofdistribution;\n(m) a precautionary statement “Keep away from the reach\nofchildren”;\n(n) in case of a veterinary medicine, a statement “For\nVeterinaryUseOnly”;and\n(o) any other information required by the Authority for\npurposes of theAct.\n(2) Wherethespaceonaprimarycontainerofmedicineisnot\nadequate to accommodate the information specified in sub-\nregulation(1),theholderofamarketingauthorisationshalllabel\ntheprimarycontainertoindicatethe—\n(a)nameanddosage formofthe medicine;\n(b)quantityorvolumeofthemedicineperunitpack;\n(c)expirydate;\n(d) name and quantity of active ingredient, or in case of a\nherbalmedicine,abotanical,Englishorothername,and\nthequantityofeachingredient;\n(e)marketingauthorisationnumber;\n(f)storageinstructions;and\n(g)batchnumber,exceptthatalltheparticularsspecifiedunder\nsub regulation (1) shall be set out on the secondary\npackage.\n(3) A holder of a marketing authorisation shall, where the\ncontainerof medicineis unabletoaccommodatetheinformation\nundersub-regulation(2),indicatethedetailsoflabellingrequirements\nforeachtype ofcontainer\nasmaybedeterminedbytheAuthority.\n(4) This regulation does not apply to medicine that is re-\npackagedfordispensing.\n(5) Despitetheotherprovisionsofthisregulation,theAuthority\nmaywaivethelabelingrequirements,asappropriate,toensurethe\nsafety,qualityandefficacyofthemedicine.\n22ndNovember,2019 Statutory Instruments 417\n21. Anoriginalcontainerofamedicineshallbeaccompanied Package\ninsertfor\nbyapackageinsertprintedinlegiblelettersinEnglishstatingthe\nmedicine\n(a)nameanddosage formofthe medicine;\n(b)nameandquantityofactivepharmaceutical ingredient,\norincaseofaherbalmedicine,abotanical,Englishor\nothername,andthequantityofeachingredient;\n(c)indications,incaseofaveterinarymedicine,specifying\ntarget species;\n(d) dosage and directions for use, in case of a veterinary\nmedicine,specifictoeachtargetspecies;\n(e) contra-indications;\n(f) side effects;\n(g) druginteractions;\n(h)precautionsandwarnings,includingwithdrawalperiods,\nincaseofaveterinarymedicineusedinfoodproducing\nanimals;\n(i) symptoms,signs,treatmentandmanagementofoverdose;\n(j)presentationofthemedicine;\n(k)descriptionofpackagingandcontainerclosuresystem;\n(l)storageinstructions;\n(m)shelflife;\n(n) name and address of the holder of the marketing\nauthorisation;and\n(o)nameofthemanufacturer,ifdifferentfromtheholderof\nthemarketingauthorisation.\n22. Aholderofamarketingauthorisationshallprovideapatient Patient\ninformation\ninformationleafletforgeneralsalemedicineandmedicineusedin\nleaflet\nchronicconditions.\n23. The Pharmacy and Poisons (Medicines) (Importation, Revocation\nofS.I.No.\nManufactureandSale)Order,1993,isrevoked.\n47of1993\n418 Statutory Instruments 22ndNovember,2019\nSCHEDULE\n(Regulations3,4,5,6,9,11,12,13,14,15,16and18)\nPRESCRIBEDFORMS\nFORMI\n(Regulations3(1)and14(5))\n(Tobecompletedintriplicate)\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nAPPLICATIONFORAMARKETINGAUTHORISATION\nShaded ApplicationNo.\nPleasecompleteinblockletters fieldsfor\nofficialuse DateandTime\nonly\nInformationRequired InformationProvided (cid:151)(cid:151)\nPARTI\nPARTICULARSOFAPPLICANT\nA. PARTICULARSOFCOMPANY\n1. (a) Nameofbusinessentity\n(b) TaxPayerIdentificationNumber(where\napplicable)\n2. Typeofbusinessentity\n3. Businesspremises\n(a) PlotNo:\n(b) Street:\n(c) TelephoneNo:\n(d) FaxNo:\n(e)MobileNo:\n(f) Emailaddress\n(g)Postaladdress\n(h)Town\n(i)District\n(j)Province\n(k)Country\nB CONTACTPERSON\n(a)Name\n(b)Designation\n(c)Physicaladdress\n(d)Postaladdress\n(e)Phone\n(f)fax\n(g)Emailaddress\nC LOCALRESPONSIBLEPERSON(Applicabletoforeignbasedapplicants)\n(a) Name\n(b) Designation\n(c)Physicaladdress\n(d)Postaladdress\n22ndNovember,2019 Statutory Instruments 419\n( )\n(e)Phone\n(f)fax\n(g)Emailaddress\nPARTII\nPARTICULARSOFTHEPRODUCT\n1. Nameofthemedicine:\n2. International non-proprietary names\nof the active pharmaceutical\ningredient, including form (salt,\nhydrate,polymorph)andstrength\n(incaseof aherbalmedicine,specify\nthe botanical, English or any other\nname and the quantities of each\ningredient)\n3. ATCcode\n4. Dosageform\n5. Routeofadministration\n6. Nameandsiteaddressofsourceof\ntheactiverawmaterial(incaseof\nherbalmedicine)\n7. Container,closureandadministration\nsystem\n8. Proposedindication(specifytarget\nspeciesincaseofveterinary\nmedicine)\n9. Packagesize\n10. Shelflife(months)\n11. Storageconditions/instructions\n12. Proposedcategoryofdistribution\n13. Marketingauthorisationstatusinother\ncountries\nPARTIII\nPARTICULARSOFMANUFACTURER\nName, address and responsibility (e.g. fabrication, packaging, labelling, testing etc.) of each\nmanufacturer, including contractors and each proposed production site or facility involved in\nmanufacturingandtestingoftheproduct:\n1. Name:\n2. Physicaladdress(include\nblock(s)/unit(s)ifapplicable\n3 Responsibility:\nIfmorethanonesiteisinvolved(e.g.manufacturingofdosageform,primarypackaging,releaseetc.),\nclearlyidentifythesiteforeachstage.\nincludecopiesofthelatestGMPcertificateformanufacturerandpackersoracopyoftheappropriate\nmanufacturinglicence\n420 Statutory Instruments 22ndNovember,2019\nPARTIV\nCOMPOSITION\nListofallcomponentsofthefinishedpharmaceuticalproductandtheiramountsonaperunit,batchand\npercentage basis including individual components of mixtures prepared in-house (e.g. coatings) and\noverages,ifany\nIngredients Function Strength(labelclaim)\nandquality (reasonfor\nstandard(in inclusion) Quantityperunit %perunit Quantityperbatch %per\ncaseofa dosageform(e.g. dosageform batch\nherbal mg/tablet)\nmedicine,\nspecifythe\nbotanical,\nenglishor\nanyother\nname\n<completewithappropriatetitlee.g.coretablet,contentsofcapsule,powderforinjection>\nSubtotal1\n<completewithappropriatetitlee.g.film-coating>\nSubtotal2\nTotal\n8. PARTV:TYPEOFAPPLICATION\nIndicatethetypeofmedicine,thetypeofdataincludedasproofofefficacy,andthe reviewprocedure\n(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:3)(cid:70)(cid:75)(cid:72)(cid:70)(cid:78)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:3)(cid:11)(cid:165)(cid:12)(cid:3)(cid:82)(cid:85)(cid:3)(cid:68)(cid:3)(cid:70)(cid:85)(cid:82)(cid:86)(cid:86)(cid:3)(cid:11)(cid:59)(cid:12)(cid:3)\nHumanMedicine NCE Dataasproofof\nefficacy:\nChemical Multisource Pre-clinical\nBiological Biosimilar Clinical\nVeterinaryMedicine: Biostudy\nChemical BCS\nbiowaiver\nBiological Bibliography\nHerbal:\nReview\nProcedure\nRoutine Abridged FastTrack\n(Expedited)\nDECLARATIONANDSIGNATURE:\nIdeclarethatalltheinformationIhavestatedinthisapplicationiscorrectandtruthfultothebestofmyknowledge\nandbelief. Iunderstandthatsubmissionoffalseinformationshallrendertheapplicationvoidandthatifapprovalis\ngranted,themarketauthorisationmayberevoked.\nParticularsofthePersonsigningonbehalfoftheApplicant\n…………………………………………………… …………………………………………………………..\nName Designation\n……………………………………………….. ……………………………………………………………\nSignature Date\nFOROFFICIALUSEONLY\nDateofSubmission:………………………………………………………………………………………………..…..\nApplicationNumber:……………………………………………………………………………………….……….…..\nPaymentsReceiptNumber:……………………………………………………………………….…….….…………...\nApplicationcomplete(Proceedforevaluation):………………………………………………………..…………..…..\nApplicationincomplete(refertoapplicantforadditionalinformation):\n………………………………………………….…………..……………………………………………………………\nOFFICIAL\nSTAMP\n22ndNovember,2019 Statutory Instruments 421\nFORMII\n(Regulations4(1))\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nREQUESTFORADDITIONALINFORMATION\nApplication No:……………………………………\nTo: ……………………………………………………………………………………….....….\nAddress: ………………………………………………………………….…………….....……..\nYou are requested to furnish, within…………………….. days of this Notice, the following\ninformationordocumentsinrespectofyourapplicationfor……………………………………….\n(a) ………………………………………………………………………………...……..\n(b) ………………………………………………………………………………………..\n(c) ………………………………………………………………………………………….\n(d) ………………………………………………………………………………………..\nIfyou failto furnishtherequestedinformation withinthestipulatedperiod, yourapplication\nwillbetreatedasinvalidandshallberejected.\nDatedthis…………………………dayof……………………………..,20…………….\n……………….…………………….\nDirector-General\nOFFICIAL\nSTAMP\n422 Statutory Instruments 22ndNovember,2019\nFORMIII\n(Regulations5(1))\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nMARKETINGAUTHORISATION\nMarketingAuthorisationNo.MA……/……\nNameofMedicine:…………………………………………………………………………………\nDosageform:……………………………………………………………………………………\nPacksize Shelflife(Months) Categoryofdistribution\n……………………...…. ……………………………. ……………………....…..\n……………………....… …………………………… …………………..………\n……………………...…. …………………………… ……………………..........\nNameofactiveingredient Quality standards Strength\n………………………… ………………………….... …………………………..\n………………………… ……………………………. …………………………..\n…………………..…….. ………………………...….. …………………………..\nNameandaddressofholderofmarketingauthorisation:\n………………………………………………………….....................................................………\n……………………………………………………………………................................................\n………………………………………………………………………………………………………………………………………………………………………\nValiduntil………………………………………………………………………….……………….\nThetermsandconditionsofthemarketingauthorisationareattachedherewith.\n……………….………………… …………………....……\nDirector-General Dateofissue\nSEAL\n22ndNovember,2019 Statutory Instruments 423\nTERMS AND CONDITIONS OF THE MARKETING AUTHORISATION\nTheholderofamarketingauthorisationshall—\n(a)ensurethatthemedicine—\n(i) ismanufacturedincompliancewiththecurrentGoodManufacturingPractices\n(cGMP)asrecommendedbytheWorldHealthOrganisation(WHO)or\nanyotherrecognisedentity;\n(ii)conformswiththequalitystandards,safetyandefficacyandissuitablefor\nthepurposeforwhichitisintended;\n(iii)conformstothesummaryofproductcharacteristics;\n(b) ensurecompliancewithgooddistributionpracticesandthatthemedicineissupplied\nin accordance with the requirements applicable to the categories of distribution\nspecifiedonthismarketingauthorisationandwithregulationsonlabelingofmedicine;\n(c) maintain an appropriate pharmacovigilance system for monitoring, detecting and\nreportingadversedrugreactionsandtheperformanceofproductsgrantedmarketing\nauthorisation;\n(d) paytotheAuthoritytheannualretentionfees,sampleanalysisfeesandotherfeesas\nprescribed;\n(e) ensurethatthemarketingauthorisationisnottransferredwithoutthewrittenapproval\nof theAuthority;\n(f)foraforeign-basedholderofmarketingauthorisation,appointalocalresponsibleperson;\n(g) notify the Authority of any change that requires an amendment to a marketing\nauthorisation;\n(h) when necessary or as directed by the Authority, withdraw any product from the\nmarketthatisinjuriousto,orislikelytobeinjurioustopublichealth;and\n(i)provideadditionalinformationorproductsamplewhenrequiredtodosobytheAuthority\nforpurposesoftheAct.\nNOTE:\nNon-compliancewithanyofthetermsorconditionsofamarketingauthorisationwillresult\ninsuspensionorrevocationofthemarketingauthorisation.\n424 Statutory Instruments 22ndNovember,2019\nFORMIV\n(Regulations6(2) and16(4)\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nNOTICEOFREJECTIONOFAPPLICATIONFORAMARKETING\nAUTHORISATION/RENEWALOFMARKETINGAUTHORISATION\nApplication No.:………………………………\n(1)Hereinsert\nTo(1)……………………………...............………………….............................\nthefullnames\nandaddressof\n………………………………………………………………………………………………………………\nthe applicant\n(2)Hereinsert INTHE MATTER OF (2) ……………………………….................... you are\nthereference\nNo.ofthe notified that your application for (3) a marketing authorisation/renewal of a\napplicationand\nthe product marketing authorisation has been rejected by theAuthority on the following\nname grounds:\n(3)Hereinsert\ntheapplicable\napplication\n(a)……………...........................……………………………………….......……\n(b)……………………………………………….....................………..……………\n(c)………………………………………………………....................…..…………………\n(d)………………………………………………………………….....................………\n.\nDatedthis……………………dayof………............………20……………...\n..........................................................\nDirector-General\nOFFICIAL\nSTAMP\n22ndNovember,2019 Statutory Instruments 425\nFORMV\n(Regulation9(1))\n(Tobecompletedintriplicate)\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nAPPLICATIONFORAMENDMENTOFMARKETINGAUTHORISATION\nShadedfields ApplicationNo.\nPleasecompleteinblockletters forofficial\nuseonly DateandTime\nInformationRequired InformationProvided (cid:151)(cid:151)\nPART1\nPARTICULARSOFAPPLICANT\nA BUSINESSAPPLICANT\n1. (a)Nameofapplicant\n(b)TaxPayerIdentificationNumber\n(whereapplicable)\n2. Typeofentity\n3. Businesspremises\n(a) PlotNo:\n(b) Street:\n(c) Postaladdress\n(d) TelephoneNo:\n(e) FaxNo:\n(f) MobileNo:\n(g) Emailaddress\n(h) Town\n(i) District\n(j) Province\n(k) Country\nB CONTACTPERSON\n(a)Name\n(b)Physicaladdress\n(c)Postaladdress\n(d)Phone\n(e)fax\n(f)Emailaddress\nC LOCALRESPONSIBLEPERSON\n(a) Name\n(b) Designation\n(c) Phone\n(d) Fax\n(e) Emailaddress\n426 Statutory Instruments 22ndNovember,2019\nPARTII\nPARTICULARSOFPRODUCT\n(a) nameoftheproduct\n(b) marketingauthorizationNo.\n(c)strength(s)\n(d)packsize(s)\n(a) dosageform\nPARTIII\nTYPEOFAMENDMENT\n4. PARTICULARSOFAMENDMENT DESCRIPTIONOFAMENDMENT(S)\n1.\n2.\n3.\n5. EXISTING PROPOSEDAMENDMENT REASONSFOR\nAMENDMENT\n6. Attachment\nRelevantdocumentsrelatingtoproposedamendmentasrequiredbytheAuthority\nDECLARATIONANDSIGNATURE\nIdeclarethatalltheinformationIhavestatediscorrectandtruthfultothebestofmyknowledgeandbelief.\nParticularsofthePersonsigningonbehalfoftheApplicant\n……………………………………………………… …………………………………………………………..\nName Designation\n……………………………………………………….. ……………………………………………………………\nSignature Date\nFOROFFICIALUSEONLY\nDateofSubmission:……………………………………………………………………………………...…………………..\nApplicationNumber:…………………………………………………………………….……………………………….…..\nPaymentsReceiptNumber:………………………………………………………….….……………………………..…….\nApplicationaccepted(Proceedforinspection):………………………………….……………………………………….….\nApplicationrejected(Notifyapplicant)………………………………………….…………………………………………..\n………………………………………………………………….…………………………………………………….………\nOFFICIAL\nSTAMP\n22ndNovember,2019 Statutory Instruments 427\nFORMVI\n(Regulation11(2))\n(Tobecompletedintriplicate)\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nAPPLICATIONFORTRANSFEROFMARKETINGAUTHORISATION\nShadedfieldsfor ApplicationNo.\nPleasecompleteinblockletters officialuseonly\nDateandTime\nInformationRequired InformationProvided (cid:151)(cid:151)\nPARTI\nPARTICULARSOFAPPLICANT\nA DETAILSOFCURRENTHOLDEROFMARKETINGAUTHORISATION\n1. (a)Nameofapplicant\n(b)TPIN\n2. Typeofentity\n3. Businesspremises\n(a) PlotNo:\n(b) Street:\n(c) TelephoneNo:\n(d) FaxNo:\n(e)MobileNo:\n(f) Emailaddress\n(g)Postaladdress\n(h)Town\n(i)District\n(j)Province\n(k)Country\nB CONTACTPERSON\n(a)Name\n(b)Physicaladdress\n(c)Postaladdress\n(d)Phone\n(e)fax\n(f)Emailaddress\nC LOCALRESPONSIBLEPERSON\n(a) Name\n(b) Designation\n(c) Phone\n(d) Fax\n(e) Emailaddress\n428 Statutory Instruments 22ndNovember,2019\nPARTII\nPARTICULARSOFTRANSFEREE\n1. (a)Nameofapplicant\n(b)TPIN\n2. Typeofentity\n3. Businesspremises\n(a) PlotNo:\n(b) Street:\n(c) Postaladdress\n(d) TelephoneNo:\n(e) FaxNo:\n(f) MobileNo:\n(g) Emailaddress\n(h) Town\n(i) District\n(j) Province\nB INDIVIDUALTRANSFEREE\n(a)Name\n(b)Physicaladdress\n(c)Postaladdress\n(d)Phone\n(e)fax\n(f)Emailaddress\nC LOCALRESPONSIBLEPERSONOFTRANSFEREE\n(a) Name\n(b) Designation\n(c) Phone\n(d) Fax\n(e) Emailaddress\nPARTIII\nPARTICULARSOFTHEMEDICINE\n1. Nameofmedicine\n2. Marketingauthorisationnumber\n3. Strength\n4. Packsize(s)\n5. Dosageform\n6. Proprietaryname\n4. ATTACHMENTS\nContractofsaleoracquisitionofbusinessbetweentheholderofmarketauthorisationandtheproposed\ntransferee\nCopyoforiginalmarketauthorisation\nDECLARATIONANDSIGNATURE\nIdeclarethatalltheinformationIhavestatedinthisapplicationiscorrectandtruthfultothebestofmyknowledge\nandbelief. Iunderstandthatsubmissionoffalseinformationshallrendertheapplicationvoidandthatifthemarket\nauthorisationisgranted,itshallberevoked.\nParticularsofthePersonsigningonbehalfoftheApplicant\n…………………………………………………… …………………………………….……………………\nName Designation\n……………………………………………..….….. ……………………………………………………….…\nSignature Date\nFOROFFICIALUSEONLY\nDateofSubmission:……………………………………………………………………..………………….…………..\nApplicationNumber:……………………………………………………………………………………….……….…..\nPaymentsReceiptNumber:……………………………………………….…….….…………………………..……….\nApplicationaccepted(Proceedforinspection):……………………………………………………..……..……..……..\nApplicationrejected(Notifyapplicant):………………………….……………………..………………………….……\n………………………………………………………………….……………………………………………….………\nOFFICIAL\nSTAMP\n22ndNovember,2019 Statutory Instruments 429\nFORMVII\n(Regulation12(2))\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nNOTICEOFINTENTIONTOSUSPENDAMARKETING\nAUTHORISATION\n(1)Hereinsert To(1)…………………………...............………………….............................\nnameofholder\nofmarketing ………………………………………………………………………………………………………………\nauthorisation\n(2)Hereinsert IN THE MATTER OF (2)..................................................you are hereby\nofmedicine notified that theAuthorityintends to suspend your marketingauthorisation\nandmarketing\nonthefollowinggrounds:\nauthorisation\nnumber\n(a)……………...........................……………………………………….......……\n(b)……………………………………………….....................………..……………\n(c)………………………………………………………....................…..…………………\n(d)………………………………………………………………….....................………\n(3)Hereinsert Accordingly,youarerequestedtoshowcausewhyyourmarketingauthorisation\nnumberof shouldnotbesuspendedandtotakeactiontoremedythebreachessetoutin\ndays\nparagraphs................... (above)within(3)................daysof receiving this\nnotice. Failuretoremedythesaidbreachesshallresultinthesuspensionof\nyourmarketingauthorisation.\nDatedthis…………………dayof………............………20……………...\n..........................................................\nDirector-General\nOFFICIAL\nSTAMP\n430 Statutory Instruments 22ndNovember,2019\nFORMVIII\n(Regulation12(3))\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nNOTICEOFSUSPENSIONOFMARKETINGAUTHORISATION\n(1)Hereinsert To(1)…………………………...............………………….............................\nnameofholder\nofmarketing ………………………………………………………………………………………………………………\nauthorisation\n(2)Hereinsert INTHEMATTEROF(2)........................................................youarehereby\nnameof notified that your marketing authorisation has been suspended for (3)\nmedicineand\n……………………..……..onthefollowinggrounds:\nmarketing\nauthorisation\nnumber (a)……………...........................……………………………………….......……\n(3)Hereinsert\nperiodof (b)……………………………………………….....................………..……………\nsuspension\n(c)………………………………………………………....................…..…………………\nAccordingly,youarerequestedtotakeactiontoremedythebreachessetoutin\nparagraphs................................................................(above)within\n(3)Hereinsert (4)................................daysofreceiving thisNotice. Failuretoremedythe\nperiodofdays\nsaidbreachesshallresultintherevocationofyourmarketingauthorisation.\nDatedthis…………………dayof………............………20……………...\n..........................................................\nDirector-General\nOFFICIAL\nSTAMP\n22ndNovember,2019 Statutory Instruments 431\nFORMIX\n(Regulation13(2))\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nNOTICEOFRESTORATIONOFMARKETINGAUTHORISATION\n(1)Hereinsert To(1)…………………………...............………………….............................\nnameofholder\nofmarketing ………………………………………………………………………………………………………………\nauthorisation\n(2)Hereinsert IN THE MATTER OF (2)....................................................you are hereby\nnameof\nmedicineand notifiedthatyourmarketingauthorisationhasbeenrestored.\nmarketing\nauthorisation\nNotethatyouarerequiredtocomplywiththetermsandconditionsattachedto\nnumber\nthemarketingauthorisation.\nDatedthis…………………dayof………............………20……………...\n..........................................................\nDirector-General\nOFFICIAL\nSTAMP\n432 Statutory Instruments 22ndNovember,2019\nFORMX\n(Regulation14(2))\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nNOTICEOFINTENTIONTOREVOKEMARKETING\nAUTHORISATION\n(1)Hereinsert To(1)…………………………...............………………….................................\nnameofholder\nofmarketing ………………………………………………………………………………………………………………\nauthorisation\n(2)Here IINTHEMATTEROF(2)..................................................youareherebynotified\ninsertnameof\nmedicineand thattheAuthorityintendstorevokeyourmarketingauthorisationonthefollowing\nmarketing\ngrounds:\nauthorisation\nnumber\n(a)……………...........................……………………………………….......……\n(b)……………………………………………….....................………..……………\n(c)………………………………………………………....................…..…………………\n(d)………………………………………………………....................…..…………………\nAccordingly,youarerequestedtoshowcausewhyyourmarketingauthorisation\nshould not be revoked for the breaches set out in paragraphs\n.......................................................................(above)within\n(3)Hereinsert (3).......................daysof receiving thisnotice. Failuretoremedythesaid\nnumberof\nbreachesshallresultintherevocationofyourmarketingauthorisation.\ndays\nDatedthis…………………dayof………............………20……………...\n.........................................................\nDirector-General\nOFFICIAL\nSTAMP\n22ndNovember,2019 Statutory Instruments 433\nFORMXI\n(Regulation14(3))\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nNOTICEOFREVOCATIONOFMARKETINGAUTHORISATION\n(1)Hereinsert To(1)…………………………...............………………….................................\nnameofholder\nofmarketing ………………………………………………………………………………………………………………\nauthorisation\n(2)Hereinsert INTHEMATTEROF(2)..................................................youareherebynotified\nnameof\nmedicineand thatyourmarketingauthorisationhasbeenrevokedonthefollowinggrounds:\nmarketing\nauthorisation\n(a)……………...........................……………………………………….......……\nnumber\n(b)……………………………………………….....................………..……………\n(c)………………………………………………………....................…..…………………\n(d)………………………………………………………....................…..…………………\nYou are therefore required to surrender the marketing authorisation to the\nAuthoritywithintwentyonedaysfromthedateofrevocation.\nYouarealsorequiredtocomplywiththetermsandconditionsattached.\nDatedthis…………………dayof………............………20……………...\n.........................................................\nDirector-General\nOFFICIAL\nSTAMP\n434 Statutory Instruments 22ndNovember,2019\nFORMXII\n(Regulation15(1))\n(Tobecompletedintriplicate)\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nAPPLICATIONFORADUPLICATEMARKETINGAUTHORISATION\nShadedfieldsforofficialuse ApplicationNo.\nPleasecompleteinblockletters only\nDateandTime\nInformationRequired InformationProvided (cid:151)(cid:151)\n1. Nameofbusinessentity/individual/localresponsibleperson\n2. MarketingAuthorisationNo.\n3. PhysicalAddress\n4. Affidavit of loss or damage to\nmarketingofauthorisation\nDECLARATIONANDSIGNATURE\nIdeclarethatalltheinformationIhavestatediscorrectandtruthfultothebestofmyknowledgeandbelief.\nParticularsofthePersonsigningonbehalfoftheApplicant\n……………………………………………………………… …………………………………………………………..\nName Designation\n………………………………………………………………….. ……………………………………………………………\nSignature Date\nFOROFFICIALUSEONLY\nDateofSubmission:…………………………………………………………………………………………………………….……..\nApplicationNumber:……………………………………………………………………………………….……….………………....\nPaymentsReceiptNumber:……………………………………………………………………….…….….………………………….\nApplicationAccepted:………………………………………………………………..…………………..……………………….…..\nApplicationRejected(Notifyapplicant):……………………..…………………………………………………………………….…\n………………………………………………………………….……………………………………………………………………....\nOFFICIAL\nSTAMP\n22ndNovember,2019 Statutory Instruments 435\nFORMXIII\n(Regulation16(1))\n(Tobecompletedintriplicate)\nTheMedicines andAlliedSubstancesAct, 2013\n(ActNo.3of2013)\nThe Medicines andAllied Substances\n(Marketing Authorisation of Medicines) Regulations, 2019\nAPPLICATIONFORRENEWALOFMARKETINGAUTHORISATION\nShadedfieldsfor ApplicationNo.\nPleasecompleteinblockletters officialuseonly\nDateandTime\nInformationRequired InformationProvided (cid:151)(cid:151)\nA PRODUCTDETAILS\n1. NameofProduct\nMarketingAuthorisationNumber\n2. Nameofholderofmarketauthorisation\n(a) TaxPayerIdentificationNumber(where\napplicable)\n(b) PlotNo:\n(c) Street:\n(d) TelephoneNo:\n(e) FaxNo:\n(f)MobileNo:\n(g) Emailaddress\n(h)Postaladdress\n(i)Town\n(j)District\n(k)Province\n(l)Country\nB CONTACTPERSON\n(a)Name\n(b)Physicaladdress\n(c)Postaladdress\n(d)Phone\n(e)fax\n(f)Emailaddress\nC LOCALRESPONSIBLEPERSON\n(a) Name\n(b) Designation\n(c) Phone\n(d) Fax\n(e) Emailaddress\n3. Attachment\nRelevantdocumentationandadditionaldataasoutlinedintheguidelinesonRenewalofMarketing\nAuthorisation\nNameofApplicant(individualorauthorisedrepresentative)\nDate:……………………………………………… Signature:………………………………………………………….\n436 Statutory Instruments 22ndNovember,2019\nFOROFFICIALUSEONLY\nReceivedby:……………………………………………… ReceiptNo:…………………………………………………..\nAmountReceived:……………………………….……….……………………………………..………………………….…\nSerialNo.ofapplication:…………………………………………………………………….……….….…………...……….\nOFFICIAL\nSTAMP\nDR C. CHILUFYA,\nLUSAKA Minister of Health\n18thNovember,2019\n[MH/101/16/1]",
  "source": "https://zambialii.org/akn/zm/act/si/2019/79/eng@2019-11-22",
  "type": "act",
  "related_files": [
    {
      "type": "pdf",
      "url": "https://zambialii.org/akn/zm/act/si/2019/79/eng@2019-11-22/source.pdf",
      "path": "lawdata\\zm_act_si_2019_79_eng@2019-11-22\\zm_act_si_2019_79_eng_2019-11-22.pdf"
    }
  ],
  "citations": []
}